Dexcom insider plans sale of 26,756 shares

Dexcom, Inc. (DXCM) has a planned sale of common stock reported by affiliate Kevin R. Sayer.

Rhea-AI Filing Summary

Dexcom, Inc. (DXCM) has a planned sale of common stock reported by affiliate Kevin R. Sayer. The notice covers up to 26,756 common shares to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with an estimated aggregate market value of $2,041,999.19 as of the filing.

The shares derive from performance and restricted stock awarded on March 8, 2021. Dexcom reports 385,872,977 common shares outstanding, a baseline figure, not the amount being sold. In the past three months, Sayer sold 26,756 shares on July 6, 2026 for $1,926,432.00 and 26,759 shares on May 21, 2026 for $1,926,648.00.

Key Figures

Planned shares to be sold: 26,756 shares Aggregate market value of planned sale: $2,041,999.19 Shares outstanding: 385,872,977 shares +2 more

5 metrics

Planned shares to be sold 26,756 shares Common stock covered by the Form 144 notice

Aggregate market value of planned sale $2,041,999.19 Estimated value of 26,756 shares to be sold

Shares outstanding 385,872,977 shares Dexcom common shares outstanding as referenced in the notice

Prior sale 1 26,756 shares for $1,926,432.00 Common shares sold on July 6, 2026

Prior sale 2 26,759 shares for $1,926,648.00 Common shares sold on May 21, 2026

Key Terms

Form 144, restricted stock, performance stock, Executive Financial Services

4 terms

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

restricted stock financial

"Performance and Restricted Stock | ISSUER"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

performance stock financial

"Performance and Restricted Stock | ISSUER"

Executive Financial Services financial

"Morgan Stanley Smith Barney LLC Executive Financial Services"

FAQ

What stock sale is Kevin R. Sayer reporting for Dexcom (DXCM)?

Kevin R. Sayer is planning to sell 26,756 common shares of Dexcom, Inc. The shares are valued at about $2,041,999.19 in total and will be sold through Morgan Stanley Smith Barney LLC Executive Financial Services.

What is the origin of the shares in Kevin R. Sayer’s Dexcom (DXCM) Form 144?

The shares in the Form 144 relate to performance and restricted stock granted on March 8, 2021. This indicates the planned sales involve equity awards rather than open-market purchases, consistent with typical executive compensation structures.

How many Dexcom (DXCM) shares did Kevin R. Sayer sell recently?

Over the past three months, Kevin R. Sayer reported selling 26,756 shares on July 6, 2026 for $1,926,432.00 and 26,759 shares on May 21, 2026 for $1,926,648.00.

What is Dexcom’s (DXCM) total common shares outstanding in this filing?

Dexcom reports 385,872,977 common shares outstanding. This number provides context for the company’s equity base and is separate from the 26,756 shares covered by Kevin R. Sayer’s planned sale under this Form 144 notice.

Which broker is handling Kevin R. Sayer’s planned Dexcom (DXCM) share sale?

The planned sale of 26,756 Dexcom common shares is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, based at 1 New York Plaza, 8th Floor, New York, NY 10004, as indicated in the Form 144 disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/20/2026 - 04:05 PM Accepted by SEC EDGAR 07/20/2026 - 04:05 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001286858
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	DEXCOM, INC.
SEC File Number	000-51222
Address of Issuer	6340 Sequence Drive San Diego CALIFORNIA 92121
Phone	(858) 200-0200
Name of Person for Whose Account the Securities are To Be Sold	KEVIN R SAYER
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	26756	2041999.19	385872977	07/20/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/08/2021	Performance and Restricted Stock	ISSUER			26756	03/08/2021	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
KEVIN R SAYER 6340 Sequence Drive San Diego CA 92121	Common	07/06/2026	26756	1926432.00
KEVIN R SAYER 6340 Sequence Drive San Diego CA 92121	Common	05/21/2026	26759	1926648.00

144: Remarks and Signature

Remarks	The securities to be sold were acquired upon the vesting of Restricted Stock and Performance Shares during the period of 03/08/2021 through 03/08/2025
Date of Notice	07/20/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	02/18/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Kevin R Sayer
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)